9RO1R-DQ0DU
-3UDSRNNODR+RVS&OLQ0HG(GXFDW&HQWHU
65
“
Cefminox (Meicelin )
..*
(Generic name)
Cefminox
(Trade name)
Meicelin£
(Therapeutic Category)
Antibiotic Cephalosporin (Cephamycin gr.) (Chemical Structure)
(Dosage form)
1 gm/vial
%& (Use)1,4-6,8-9
9! :*, $% , aerobic gram positives, aerobic gram nega
!"# "$# (Pharmacology) 1,3 tive $ anaereobic organisms , ! "# $% Streptococcus sp., Staphylococcus sp.,
&'*&
+,",,-! Haemophillus influenzae, Escherichia. coli,
"0& 2*3$45,'6 7& - beta Klebsiella pneumoniae, Proteus sp., Bacteroi-lactams peptidoglycan des fragilis 9!3<*,
$ lipoprotein $%
0
, * , colorectal surgery, Hysterec9! $*
"#$%
tomy prophylaxis 2*!
* x·uŽž jwŠwuŽž {f{Žf
66 ‹}„‹}‚‘Ù|Äc‹}‚cƒ‹—Üu|‚‹„s}ÄfÙc ˜}hÜ|‹w‹Ü}Ýxc–cÁ‹
&&
5 7
%' (Dose)
*,9!9> 7 2 '
@
!
3 '$9!
7 2 % 9& *,
& $
B
+,& -!> 6 *7 '
$9! 3-4 %
*,9
G % 20 mg/kg
'@
!
3 '$
9!7 3-4 %
*,*
G77!>%7
9!39
!* 9*% #& %#P9!
*$* 7- 39 # 37 52 -
+!>739!
,%7,*,9
%# -G*
&3
%79!9*% # 0-%79! *% #& 73
%# 7!$*9> +,, $+#
*+$
!."/!0#2/
( Special Populations) 1,3
$#: & (Administration )
9!'@
!
3 9!
9! 9!> J 7 & 3-*
+ %7 Cefminox * *7 0.5 $ 1.0 93& 3
@ dextrose ,
3-* %'*-# ,* 10 . $ 20 . *
creatinine
3 $@
!! R
clearances ( Clcr )
9!'
!
3 9!
*7 0.5 $ 1.0 93& 3
>30 ml/min/1.73m2
1 @ dextrose 7 2 %
,
%'*-# ,* 50-250 . $ 10010 - 30 ml/min/1.73m2
1 500 . *3 $9!
7 1-2 7& '
7%
<10 ml/min/1.73m2
500 ,,
7%
9!> 7J & 3
-*+ %7%7B& 12 7& '-7!
$!7
- %0& 0& 9!> 7J & % Clcr 10-30 ml/min
- 0& 9& 7 9!>
J7& % Clcr <10 ml/min
%
$$" (Warnings/ Precautions)
- 79!9!>J7&7*,
$+! +,", ,
- !> 7J -& *3+$
- !>J7& -!
!
!> 7J > !> 7J & $! (%79!$!>J 7
+!
*>$
++ & +7
7,*, K ,0 -!)
9RO1R-DQ0DU
-3UDSRNNODR+RVS&OLQ0HG(GXFDW&HQWHU
67
&&$U#97:$
- - % 79! 9 !> J 7 & 7 *, $ +! ! 1 #:
G, $!7
Cefminox $+! Cephamycin ,& R
%&
%
(Adverse Reactions)
7
- Anaphylaxsis shock (+-!! )
- ,7 : & ,7$ %
$
2-!
- -
7',* : G
$ U'*%,$U'', granulocyte ,*, 37
G
$
prothrombin time 0
- ** : 3*,*,
+,&>0% GOT, GPT alkaline
phosphatate, gamma GPT, LAP, LDH $
bilirubin " +!
- , : !
%&
-! 7! & 7!
- ,9: 93 -
- 7 : Vertigo,
dizziness
- ! % & R : Pseudomembranus colitis, Double vision, Palpitation,
Bitterness, Excitation, Aphthous stomatitis __
"## "$
(Drug Interactions)
- 9!7`7 Furosemide 39!
,%7
2+,:*-* %77
& 9! 7 7
- 45,%6 ! disulfiram "0& $U# 39!%7
!!
aldehyde 9
> %7
& %& $#<="/ .
$
"$%
(Storage and Stability)
G& P
>, ! % (Shelf-life)
2 q
2>/
.## (Clinical trial )
#<#*." ?
1. !"#$%&!'$*+
!' Cefminox &! Metronidazole ' * Gentamicin * Intra-abdominal infection 8
Torres AJ $%P 30:$
prospective, open paralle randomized, multicenter trial 9!> 7J 37 160 $!>
J7-
%-!|,79R 9 72 7& '0: !>
J7-! * $* 3*B, :7*, 9 ! (
appendicitis, cholecystitis, gastric perforation,
intestinal perforation, colon perforation ) '
!> 7J -! Cefminox 9 2 IV
$9! 12 7& ' 37 80 $-!
Metronidazole 500 ,, 8
7& ' 7 Gentamicin 80 ,, 8 7& ' 37 80 9!*7
,P
9 serum $ peritoneal fluid
+&>**:!7
7!>J7 0:!>J7-!
,:
%,, 37 152 $
2 72 +!> 7J !
7:!7 Cefminox
37 1 $ Metronidazole 7
Gentamicin 37 3 *3 $*
-$** 3%B,*, (RR:1.07,
95%CI 1-1.15) 0:+7 cure rate
9!
98.6% 9 Cefminox
$ 92.1% 9 Metronidazole 7
Gentamicin *3 '!> 7J *%,,*:!7-
$** 3%B,*, 7 ,$*,
9! 7
:9'+$
7&9!9
: -% 7$** 3%
B,*,7!> 7J 90:%
& 2 * '%& + 7 9 % Escherichia coli $ Bacteroides fragilis $
!> 7J ,-+0 %#
37 , 11 '%7$
-+0 %#9!B0
2. !"#!' Cefminox &!
Cefoxitin Hysterectomy prophylaxis 9
Garrido R. $%P -!30:$
prospective, randomized, controlled clinical
trial 9!> 7J ,37 112 & !
3*B gynaecological surgery (vaginal
abdominal Hysterectomy) !> 7J 59 -! Cefminox 2 @
!
37 15 3*B 30 37 1 dose $ !>
J7 53 -! Cefoxitin 2 @
!
37 15 3*B 30 9! "3
& 4 7& ' $ 8 7& ' *3 7
, 3 dose 9!3*77
%7
! ! 9
Peak,
intraoperative $ Trough serum concentrations 7!> 7J -& ! 7
%7
!!
9 myometrial tissue 9 subset !> 7J & !70:% 37 40 $
2!> 7J 9 Cefminox 22 $9
Cefoxitin 37 18 *3 0:+7!> 7J -& ! *
%,, -$** 3%
B,*, '-!9! 7
:9'+$
,-+0
%#9! -% 7$**
3% B, *, 7 !> J 7 $ Peak serum concentrations %
132.3 mg/L 9 Cefminox $ 82.2 mg/L
9 Cefoxitin *3 12-hour concentrations % 2.82 mg/L 9 Cefminox $ 2.17 mg/L 9 Cefoxitin
*3 "0& %7
!!7& -!>
7% MIC 9 +& -! 9P
Hysterectomy prophylaxis *77 uterine
tissue concentrations %
24.5 mg/L
9 Cefminox $ 41.6 mg/L 9 Cefoxitin *3 "0& >7% MIC
!' Cefminox &! Cefoxitin 1,2,3,7,9
,/"*0 1) %7-7
*
1.1) Gram negative
1.2) Gram Positive
1.3) Anaerobe (B. Fragilis)
2) Half life
3) Cmax (mg/L), after 2 gm IV
4) Dose administration
Cefminox
Cefoxitin
++++
+++
++++
2.48 hr
130.25
Bid (2-4 g/day)
+++
+++
++
0.8 hr
82.24
Qid (4 g/day)
#
Cefminox 2 Cephalosporin
(Cephamycin gr.) & 45,96 $%
, aerobic gram positives, aerobic gram negative $ anaereobic organisms
, Streptococcus sp., Staphylococcus
sp., Haemophillus influenzae, Escherichia.
coli, Klebsiella pneumoniae, Proteus sp.,
Bacteroides fragilis 0:
%,,+7 Cefminox ,5,+
$%79:*,
$%
7 7 ,5,+$
%79<*,
*-$** Cefoxitin , colorectal surgery, Hysterectomy prophylaxis
2*! -G 9! Cefminox 3
<*,
* %7+,P
9!
&%
$+79 first generation cephalosporin $|,779&9!3
<*,
*&>
,9
'+ $
+& %7
& * 9%*
1. Watanabe S, Omoto S. Pharmacology
of cefminox, a new bactericidal
cephamycin. Drug Exptl Clin Res
1990;16:461-7.
2. Damaso D. et al. Should cefminox
substute cefoxitin in infections cause by
bacteria susceptible to both drug. Rev
Exp Quimioter 1999;12:325-31
3. Dianne B. et al. In vitro activities of
cefminox against anaerobic bacteria
compared with those of nine other compounds. Antimicrob Agents Chemother
1998:495-501.
4. Omoto S, Watanabe S. Efficacy of
cefminox in the treatment of bacterial infection. Int J Clin Pharm Res
1990;10:361-8.
5. Ronald K, Woods, Dellinger EP. Current
guidelines for antibiotic prophylaxis of
surgical wounds.[serial online]. Available
from :URL : http//www.aafp.org/afp/
70
‹}„‹}‚‘Ù|Äc‹}‚cƒ‹—Üu|‚‹„s}ÄfÙc ˜}hÜ|‹w‹Ü}Ýxc–cÁ‹
x·uŽž jwŠwuŽž {f{Žf
980600ap/woods.html [Accessed 23 8. Torres AJ, Valladares LD, Jover JM,
Sanchez-Pernaute A, Frias J, Carcas AJ.
march 2009].
et al. Cefminox versus metronidazole plus
6. The Medical Letter. [serial online]
gentamicin in intra_abdominal infection:
2006;4(52). Available from : URL : http:/
a prospective randomized controlled trial.
/www.medicalletter.org.htm [Accessed 15
Infection 2000;28:318-22.
march 2009].
7. Mayama T, Koyama Y, Sebata K, Tanaka 9. Garrido R, Novo J, Quintana S, Macia
MA, Carrasco L, Dios de MJ. et al.
Y, Shirai S, Sakai H. Postmarketing surCefminox versus cefoxitin in hysterectomy
veillance on side-effect of cefminox soprophylaxis :clinical efficacy and serum
dium Int J Clin Pharm and Ther
and tissue concentrations. Clin Drug
1995;32:149-55.
Invest 1997;13:317-25.